ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.
Mon, 16 Sep 2024 02:25:00 GMT The consensus estimate for this Zacks Rank #1 (Strong Buy) company’s 2024 sales is pegged at $8.1 billion, indicating a 13.7% rise from 2023. The consensus mark for Intuitive Surgical’s 2024 EPS is ...
Sat, 14 Sep 2024 00:05:00 GMT Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today a ...
Fri, 13 Sep 2024 05:03:20 GMT Q2 2024 Earnings Call Transcript September 12, 2024 Operator: Thank you for standing by, and welcome to the Innate Pharma First-Half 2024 Financial Results and Business Update. All lines have been ...
Thu, 12 Sep 2024 16:35:00 GMT A live audio webcast can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company’s ...
Thu, 12 Sep 2024 07:16:00 GMT The lamellar ichthyosis market landscape is expected to evolve with increased interest from pharmaceutical companies in developing new treatments, advancements in diagnostic techniques, and the ...
